Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...

Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

Celltrion Inc., a leading South Korean biopharmaceutical company, said Thursday it will repurchase 100 billion won (US$73 million) worth of its own shares as part of its corporate value-up program.

South Korean biopharmaceutical firm Celltrion said Tuesday that it had released its denosumab biosimilars, Stoboclo and ...

INCHEON, South Korea, June 15, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA ® (ustekinumab ...

INCHEON, South Korea, May 23, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA ...

Celltrion has been increasing its return to shareholders, as evidenced by cash dividends increasing to KRW 153.8 billion in 2024 from KRW 51.7 billion in 2022.

Abpro and Celltrion announce a partnership to develop ABP-102/CT-P72, a promising therapy for HER2-positive cancers. Quiver AI Summary. Abpro Holdings, Inc. and Celltrion have announced a ...

LONDON, June 19, 2025--Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK, reinforcing the company’s dedication to long-term growth and ...

INCHEON, South Korea, May 21, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA ...